These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 22104015)
1. Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial. Chrispijn M; Drenth JP Trials; 2011 Nov; 12():246. PubMed ID: 22104015 [TBL] [Abstract][Full Text] [Related]
2. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726 [TBL] [Abstract][Full Text] [Related]
3. Medical therapy for polycystic liver disease. Khan S; Dennison A; Garcea G Ann R Coll Surg Engl; 2016 Jan; 98(1):18-23. PubMed ID: 26688394 [TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206 [TBL] [Abstract][Full Text] [Related]